SCHEMBL4086042

SCHEMBL4086042

Cc1cc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)cc(NS(=O)(=O)c2ccccc2F)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.52
NTRK2 Q16620 3/20 0.52
NTRK3 Q16288 2/20 0.52
KCNH2 Q12809 3/20 0.51
PDPK1 O15530 9/20 0.49
PDGFRB P09619 1/20 0.47
RET P07949 3/20 0.45
EGFR P00533 2/20 0.45
ERBB2 P04626 2/20 0.45
ERBB3 P21860 2/20 0.45
TEK Q02763 2/20 0.45
ERBB4 Q15303 2/20 0.45
LCK P06239 2/20 0.45
SRC P12931 2/20 0.45
EIF2AK3 Q9NZJ5 1/20 0.44
AKT1 P31749 6/20 0.42
MTOR P42345 6/20 0.42
AURKA O14965 1/20 0.41
GSK3B P49841 1/20 0.41
MARK1 Q9P0L2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4086058 0.90 NTRK1 (0.50) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4076485 0.89 NTRK1 (0.64) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4078414 0.85 NTRK1 (0.67) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL1939947 0.84 PDGFRB (0.62) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4081490 0.84 PDPK1 (0.55) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4080442 0.83 NTRK1 (0.58) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL1942841 0.81 EIF2AK3 (0.53) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4079511 0.80 NTRK1 (0.49) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL1941376 0.79 EIF2AK3 (0.51) NTRK1NTRK2NTRK3KCNH2PDPK1
SCHEMBL4086560 0.79 NTRK1 (0.64) NTRK1NTRK2NTRK3KCNH2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595325-B2 Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment PFIZER INC. (US) 2009-09-29 US disclosed
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment PFIZER INC 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035912-A1 Pyrrolopyrimidine derivatives useful in cancer treatment TP53, DPYD, CCNT1 NTRK1 3916/4885NTRK2 4246/4885NTRK3 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.